Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer

Inhibrx (Nasdaq: INBX) will webcast a clinical update on ozekibart (INBRX-109) on Tuesday, April 21, 2026 at 1:30 p.m. PT.

Rhea-AI Summary

Inhibrx (Nasdaq: INBX) will webcast a clinical update on ozekibart (INBRX-109) on Tuesday, April 21, 2026 at 1:30 p.m. PT. The presentation covers Phase 1/2 data for ozekibart plus FOLFIRI in locally advanced or metastatic, unresectable colorectal cancer.

Investors can join via webcast or telephone; the presentation will be archived for 60 days and the corporate presentation updated on the Investors page.

Argus Apr 21 session

+2.06% close to close Open Argus

Details

News Market Reaction – INBX

In the Apr 21 session, INBX gained 2.06%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets up a focused clinical update on ozekibart in combination with FOLFIRI for loc...

Analysis

This announcement sets up a focused clinical update on ozekibart in combination with FOLFIRI for locally advanced or metastatic, unresectable colorectal cancer, following prior disclosures of encouraging activity in late-line settings. Historically, INBX has seen stronger reactions around detailed ozekibart data than around logistics alone. Investors may watch for progression-free survival and response metrics on future updates, and compare them with earlier expansion cohort results and prior registrational success in chondrosarcoma.

Key Figures

Webcast date: April 21, 2026 Webcast time: 1:30 p.m. PT Webcast replay window: 60 days +2 more

Webcast date

April 21, 2026

Date of clinical update webcast for ozekibart in colorectal cancer

Webcast time

1:30 p.m. PT

Scheduled start time for the April 21, 2026 webcast

Webcast replay window

60 days

Duration webcast will remain available after the event

Dial-in number

1-888-880-3330

U.S. phone number to access the clinical update call

Conference ID

9536529

Conference identifier required when dialing into the webcast

Historical Context

5 past events · Latest: Mar 19

5 events

1. Mar 19

   FY 2025 earnings

   24h Move

   -6.1%

   Reported 2025 net loss and detailed reduced R&D and G&A spending.

2. Mar 02

   Conference participation

   24h Move

   -4.1%

   Announced ESMO sarcoma and rare cancers data presentation for ozekibart.

3. Dec 16

   Clinical pipeline update

   24h Move

   +1.9%

   Provided progress on INBRX-106 and ozekibart expansion cohorts and timelines.

4. Nov 14

   Q3 2025 earnings

   24h Move

   +6.0%

   Reported ozekibart registrational success plus interim data and financial metrics.

5. Nov 04

   Conference schedule

   24h Move

   +0.3%

   Outlined multiple November presentations featuring ozekibart and DR5 data.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

phase 1/2, folfiri, metastatic, unresectable colorectal cancer

4 terms

phase 1/2 medical

"Phase 1/2 study evaluating ozekibart (INBRX-109) in combination with FOLFIRI"

Phase 1/2 is a combined early-stage clinical trial that first tests a new drug or treatment for safety and the right dose, then quickly expands to check if it shows any signs of working in patients. For investors, results from a Phase 1/2 study offer an early read on both risk and potential reward—like a prototype test that both confirms a product won’t harm users and suggests whether it could sell—helping guide valuation and development decisions.

folfiri medical

"combination with FOLFIRI in patients with locally advanced or metastatic"

FOLFIRI is a chemotherapy combination used to treat certain cancers, made from the drugs fluorouracil (5-FU), leucovorin, and irinotecan — think of it as a three‑ingredient recipe designed to attack cancer cells in different ways. Investors care because its use affects demand for related drugs, influences clinical trial and approval outcomes, and can drive revenue or cost pressures for companies involved in manufacturing, supplying supportive care, or developing competing therapies.

metastatic medical

"patients with locally advanced or metastatic, unresectable colorectal cancer"

Metastatic describes cancer that has spread from its original spot to other organs or tissues, like weeds moving from one garden bed into several others. For investors, metastatic disease matters because it often requires more complex, long-term treatments, larger clinical trials, and can drive demand for specialized drugs and diagnostics—factors that affect a drug’s development costs, regulatory risk, market size, and potential revenue.

unresectable colorectal cancer medical

"patients with locally advanced or metastatic, unresectable colorectal cancer (CRC)"

A form of colorectal cancer that cannot be removed completely by surgery because the tumor has spread too far or is too close to vital structures. For investors, this matters because it means patients usually need long‑term drug treatments, radiation, or other non‑surgical therapies, which drives demand for medications, affects trial designs and regulatory paths, and influences expected healthcare costs and company revenue potential.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

– Event to be webcast live on Tuesday, April 21, 2026, at 1:30 p.m. PT –

SAN DIEGO, April 20, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced that it will host a live webcast presentation on Tuesday, April 21, 2026 at 1:30 p.m. Pacific Time to provide a clinical update from its Phase 1/2 study evaluating ozekibart (INBRX-109) in combination with FOLFIRI in patients with locally advanced or metastatic, unresectable colorectal cancer (CRC).

Investors may join via the web: https://app.webinar.net/JqrDlM8B4ak or may listen to the call by dialing (1-888-880-3330). Please refer to Inhibrx Biosciences, Inc. or the conference ID 9536529 when calling in. Following the webcast, the presentation may be accessed through a link on the "Events and Presentations" section of Inhibrx's website. The webcast will be available for 60 days following the event. Following the presentation, Inhibrx will also update its corporate presentation within the "Investors" section of its website at www.inhibrx.com.

About ozekibart (INBRX-109)
Ozekibart is a precision-engineered, tetravalent death receptor 5 (DR5) agonist antibody designed to exploit the tumor-biased cell death induced by DR5 activation. In January 2021, the FDA granted Fast Track designation to ozekibart for the treatment of patients with metastatic or unresectable conventional chondrosarcoma, and, in November 2021, the FDA granted orphan drug designation to ozekibart for chondrosarcoma.

In June 2021, Inhibrx initiated a randomized, blinded, placebo-controlled, registrational trial of ozekibart in metastatic, unresectable conventional chondrosarcoma. The trial enrolled a total of 206 patients across 67 different sites worldwide. In October 2025, Inhibrx announced the ChonDRAgon study met its primary endpoint of a statistically significant and clinically meaningful median progression-free survival (PFS) for patients with advanced or metastatic chondrosarcoma treated with ozekibart compared to placebo. Ozekibart achieved a 52% reduction in the risk of disease progression or death compared to placebo (stratified Hazard Ratio [HR] 0.479; 95% CI: 0.33, 0.68); P<0.0001), more than doubling median PFS to 5.52 months versus 2.66 months for placebo. Importantly, ozekibart is the first investigational therapy to demonstrate a significant PFS benefit in a randomized trial for chondrosarcoma, a disease with no approved systemic options.

Additionally, in Phase 1/2 trials, Inhibrx is investigating ozekibart in colorectal cancer in combination with FOLFIRI and Ewing sarcoma in combination with irinotecan/temozolomide, as well as other tumor types.

About Inhibrx Biosciences, Inc.

Inhibrx Biosciences is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates. Inhibrx Biosciences utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms. Inhibrx Biosciences was incorporated in January 2024 as a direct, wholly-owned subsidiary of Inhibrx, Inc. Prior to the sale of Inhibrx, Inc. and the INBRX-101 program to Sanofi S.A., Inhibrx Biosciences acquired certain corporate infrastructure and other assets and liabilities through a series of internal restructuring transactions effected by Inhibrx, Inc. Inhibrx, Inc. also completed a distribution to holders of its shares of common stock of 92% of the issued and outstanding shares of Inhibrx Biosciences. Following such transactions, Inhibrx Biosciences' current clinical pipeline of therapeutic candidates includes ozekibart and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what we believe to be the most appropriate agonist function. For more information, please visit www.inhibrx.com.

Forward-Looking Statements

Inhibrx cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Inhibrx's current beliefs and expectations. These forward-looking statements include, but are not limited to, statements regarding the clinical development of ozekibart. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Inhibrx's business, including, without limitation, risks and uncertainties regarding: the initiation, timing, progress and results of its preclinical studies and clinical trials, and its research and development programs; its ability to advance therapeutic candidates into, and successfully complete, clinical trials; its interpretation of initial, interim or preliminary data from its clinical trials, including interpretations regarding disease control and disease response; results from preclinical studies or early clinical trials not necessarily being predictive of future results; unexpected adverse side effects or inadequate efficacy of its therapeutic candidates that may limit their development, regulatory approval and/or commercialization; the potential for its programs and prospects to be negatively impacted by developments relating to its competitors, including the results of studies or regulatory determinations relating to its competitors; the timing or likelihood of regulatory filings and approvals and regulatory developments in the U.S. and foreign countries; the successful commercialization of its therapeutic candidates, if approved; an accelerated development or approval pathway may not be available for ozekibart or other therapeutic candidates and any such pathway may not lead to a faster development process; it may not realize the benefits associated with orphan drug designation, including that orphan drug exclusivity may not effectively protect a product from competition and that such exclusivity may not be maintained; the pricing, coverage and reimbursement of its therapeutic candidates, if approved; its ability to utilize its technology platform to generate and advance additional therapeutic candidates; and other risks described from time to time in the "Risk Factors" section of its filings with the U.S. Securities and Exchange Commission, including those described in its Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q, and supplemented from time to time by its Current Reports on Form 8-K as filed from time to time. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Inhibrx undertakes no obligation to update these statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Investor and Media Contact:

Kelly Deck, CFO
ir@inhibrx.com
858-795-4260

View original content to download multimedia:https://www.prnewswire.com/news-releases/inhibrx-to-host-webcast-presentation-to-provide-clinical-update-on-ozekibart-inbrx-109-in-late-line-colorectal-cancer-302747780.html

SOURCE Inhibrx Biosciences, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Inhibrx (INBX) presenting its clinical update on ozekibart (INBRX-109)?

The webcast is scheduled for April 21, 2026 at 1:30 p.m. PT. According to the company, the live presentation will provide a Phase 1/2 update on ozekibart plus FOLFIRI in advanced or metastatic colorectal cancer and will be available afterward for 60 days.

What clinical data will Inhibrx (INBX) discuss about INBRX-109 in the April 21, 2026 webcast?

Inhibrx will provide a Phase 1/2 clinical update on INBRX-109 combined with FOLFIRI. According to the company, the presentation focuses on results and clinical context for patients with locally advanced or metastatic, unresectable colorectal cancer.

How can investors access the Inhibrx (INBX) April 21, 2026 webcast on ozekibart?

Investors may join the live webcast at the provided webinar URL or dial 1-888-880-3330. According to the company, callers should reference Inhibrx or conference ID 9536529 and the archived webcast will be available for 60 days.

Will the Inhibrx (INBX) ozekibart webcast be available after April 21, 2026?

Yes. The webcast will be archived and available for 60 days following the event. According to the company, the presentation will also be posted in the Events and Presentations section and the Investors page will receive an updated corporate presentation.

What patient population is the INBRX-109 (ozekibart) update targeting in the Inhibrx (INBX) webcast?

The update targets patients with locally advanced or metastatic, unresectable colorectal cancer. According to the company, the data discussed come from a Phase 1/2 study of INBRX-109 in combination with FOLFIRI in that patient population.

Will Inhibrx (INBX) update its investor presentation after the April 21, 2026 webcast?

Yes. Inhibrx will update its corporate presentation in the Investors section of its website after the webcast. According to the company, the refreshed presentation will reflect the clinical update and be accessible via the Events and Presentations page.